Rigel Pharmaceuticals, Inc.

NasdaqGS:RIGL Stock Report

Market Cap: US$289.6m

Rigel Pharmaceuticals Future Growth

Future criteria checks 5/6

Rigel Pharmaceuticals is forecast to grow earnings and revenue by 45% and 13.4% per annum respectively. EPS is expected to grow by 43.8% per annum. Return on equity is forecast to be 136.5% in 3 years.

Key information

45.0%

Earnings growth rate

43.8%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate13.4%
Future return on equity136.5%
Analyst coverage

Good

Last updated10 Dec 2024

Recent future growth updates

Recent updates

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop

Dec 20
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30
There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Oct 10

Rigel Pharma adds ~7% to reach over two month high

Aug 18

Rigel rises 17% on strong Q2 result

Aug 03

Rigel Pharmaceuticals: A Status Check

May 31

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Apr 21
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Earnings and Revenue Growth Forecasts

NasdaqGS:RIGL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262263839N/A6
12/31/2025194206N/A6
12/31/20241699N/AN/A6
9/30/202415741011N/A
6/30/2024130-14-13-12N/A
3/31/2024119-20-7-7N/A
12/31/2023116-25-21-6N/A
9/30/2023129-24-36-21N/A
6/30/2023121-38-49-33N/A
3/31/2023125-45-67-52N/A
12/31/2022116-59-74-74N/A
9/30/202286-83-71-71N/A
6/30/202287-85-68-68N/A
3/31/202277-85-10N/A
12/31/2021139-1856N/A
9/30/2021138-1589N/A
6/30/2021136-8-10N/A
3/31/2021131-11-70-69N/A
12/31/2020109-30-53-52N/A
9/30/2020106-28-48-46N/A
6/30/2020108-25-43-41N/A
3/31/2020102-28-46-44N/A
12/31/201959-67-43-42N/A
9/30/201982-46-21-20N/A
6/30/201966-59-26-26N/A
3/31/201957-64-37-36N/A
12/31/201845-70-60-59N/A
9/30/20187-100-91-90N/A
6/30/20183-93N/A-88N/A
3/31/20181-87N/A-80N/A
12/31/20174-78N/A-78N/A
9/30/20177-68N/A-70N/A
6/30/201710-73N/A-75N/A
3/31/201719-67N/A-74N/A
12/31/201620-69N/A-76N/A
9/30/201626-66N/A-77N/A
6/30/201635-50N/A-64N/A
3/31/201632-51N/A-64N/A
12/31/201529-51N/A-23N/A
9/30/201529-61N/A-25N/A
6/30/201516-75N/A-34N/A
3/31/201510-87N/A-35N/A
12/31/20148-91N/A-70N/A
9/30/20146-85N/A-74N/A
6/30/20146-88N/A-76N/A
3/31/20147-86N/A-77N/A
12/31/20137-89N/A-86N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RIGL's forecast earnings growth (45% per year) is above the savings rate (2.6%).

Earnings vs Market: RIGL's earnings (45% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: RIGL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RIGL's revenue (13.4% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: RIGL's revenue (13.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RIGL's Return on Equity is forecast to be very high in 3 years time (136.5%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 08:33
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rigel Pharmaceuticals, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBarclays
Clarence PowellBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets Equity Research